LYPHE

Lyphe Group operates as a vertically integrated entity within the UK's medical cannabis sector, establishing a comprehensive ecosystem that spans from product manufacturing to patient care. Founded in 2018 by Jonathan Nadler, Rob Reid, Stephen Murphy, and Ben Langley, the company was established to improve patient access to medical cannabis treatments. Jonathan Nadler, a co-founder who also served as CEO, has a background in entrepreneurship, including founding a profitable business at 24 and exiting a strategic consultancy and a CBD company before co-founding The Academy of Medical Cannabis, which served as a precursor to his role at Lyphe Group.

The company's business model is structured around a direct-to-patient, technology-first approach, creating a supply chain that delivers medical prescriptions directly to consumers' homes. This integrated system includes telehealth consultations via its Lyphe Clinic, a pharmacy and dispensing service through Dispensary Green, and educational resources for healthcare professionals via The Academy of Medical Cannabis. Lyphe Clinic provides patients with video consultations with doctors experienced in prescribing cannabis for conditions related to pain, neurology, and psychiatry. The Academy of Medical Cannabis offers online, evidence-based training modules for clinicians to build the knowledge and confidence required to prescribe cannabis-based medicinal products. Revenue is generated through these clinical services, the sale and dispensing of medical cannabis products, and educational programs.

Significant milestones for the company include a Series A funding round of £5 million in May 2022, led by Leafy Tunnel and Sharp Capital Advisors, to fuel European expansion. This followed a period of substantial growth in 2021, where revenue increased by over 250% year-over-year. The company has held a significant position in the UK market, at times accounting for approximately 30-40% of patients. In early 2023, Lyphe underwent a significant restructuring to refocus on its core UK market and expand into Australia, which involved changes to its board and management team. The holding company, Lyphe Group Ltd, entered administration in late 2023 due to cash flow and supply chain challenges; however, its operational subsidiaries, including Lyphe Clinic, continued to trade. The business and its assets were subsequently sold to Eezy Group in December 2023, a new entity established by a former director, ensuring the continuation of its mission.

Keywords: medical cannabis UK, telehealth cannabis clinic, cannabis prescription service, cannabinoid medicine, doctor education cannabis, online pharmacy cannabis, Lyphe Clinic, Dispensary Green, The Academy of Medical Cannabis, patient access cannabis, cannabis supply chain, digital healthcare, alternative medicine, chronic pain treatment, neurology cannabis, psychiatry cannabis, Jonathan Nadler, Rob Reid, European cannabis market, cannabis investment